Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Alliancebernstein L.P.

Alliancebernstein L.P. lifted its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,630 shares of the company’s stock after buying an additional 889 shares during the period. Alliancebernstein L.P.’s holdings in Amphastar Pharmaceuticals were worth $1,880,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of AMPH. TD Private Client Wealth LLC raised its holdings in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after buying an additional 388 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares in the last quarter. KBC Group NV raised its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 8.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after acquiring an additional 801 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Amphastar Pharmaceuticals by 8.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,195 shares of the company’s stock worth $379,000 after purchasing an additional 833 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMPH shares. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $23.35 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a market capitalization of $1.11 billion, a PE ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79. The company’s 50 day moving average price is $27.96 and its 200 day moving average price is $37.53.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 27.10% of the stock is currently owned by corporate insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.